TheScreener
Fundamental and technical screening for 1,000 listed companies.
Use ⌘K to search stocks, screens, and features instantly.
Apollo Hospitals Enterprise Ltd.
APOLLOHOSPLarge CapNSEBSE
Healthcare · Healthcare
₹8,849.50up 11.00up 0.12 percentas of 31 Aug 2026
Book value ₹659.92Div yield 0.23%
Key metrics
- Market Cap
- 1,27,335.69 ₹ cr
- P/E
- 65.49 x
- P/B
- 13.41 x
- ROE
- 7.72%
- ROCE
- 9.72%
- Debt to Equity
- 0.36 x
- Net Margin
- 14.41%
- Dividend Yield
- 0.23%
- Revenue Growth (YoY)
- 20.56%
Observations
Mechanical observations generated from stored data, not analysis or opinion. Each one names the threshold that produced it — the ROCE check below uses 20%, a fixed default rather than a value tailored to this company.
- ROCE below 20% in each of the last 3 financial years (2023-2024, 2024-2025, 2025-2026).
- Revenue grew year-on-year in each of the last 3 years.
- Net margin declined year-on-year in 1 of the last 3 years.
- Promoter holding 28.0% (pledge data not available).
- Debt-to-equity 0.36 — above the Healthcare median of 0.31.
APOLLOHOSP
₹8,849.50up 0.12 percent
EOD Synced: 31 Aug 2026 18:30 ISTOverview & Live Price Chart
Executive Investment Verdict & Quality Synthesis
Autonomous V2Multi-dimensional quantitative synthesis across capital efficiency, forensic accounting, intrinsic valuation, and ownership governance.
Factual Quantitative Consensus
1. Capital Efficiency & MoatStable Return Franchise
18.36%ROCE
ROE: 20.48%·P/B: 13.41x
2. Forensic Health & SolvencyPiotroski 8/9 · Strong Health
8/9Piotroski Score
Altman: 2.8 (Safe Zone)
3. Valuation & DCF Spread-95.7% Valuation Premium
₹379DCF Fair Value
CMP: ₹8,849.5
4. Ownership & GovernanceClean Promoter Holding
28.02%Promoter Stake
Pledged: 0.0%·Inst: 58.82%
Institutional Factor Scores
QVGM Factor Grade Matrix
Institutional Multi-Factor Profile (QVGM)
Composite 0–100 percentile ranks normalized across all 500 universe constituents
Rank #33 of 46 in HealthcareQVGM 47/100
Quality (Q)41
ROE, ROCE, Margins & Cash Conversion
Value (V)16
P/E, P/B, EV/EBITDA vs Sector Benchmarks
Growth (G)68
3Y Sales & EPS Compounded Growth
Momentum (M)69
Relative Strength & Trend Position
TheScreener Radar™ 5-Pillar Quantitative Scorecard
Holistic quantitative radar evaluating fundamental quality, valuation multiples, balance sheet health, growth, and price momentum
Sector Rank:Rank #33 of 46 in Healthcare
Valuation
Weak16/100
P/E Ratio:65.49x
P/B Ratio:13.41x
Dividend Yield:0.23%
P/E, P/B, EV/EBITDA & Dividend Yield relative to 5Y medians and sector
Growth
Moderate68/100
3Y Sales CAGR:—
3Y PAT CAGR:—
Quarterly YoY:+12.4%
3-Year Compounded Sales & Net Profit Growth trajectory
Profitability
Moderate41/100
ROE:20.5%
ROCE:18.4%
OPM %:—
Return on Equity (ROE), ROCE & Operating Margin efficiency
Solvency & Health
Strong89/100
Piotroski F-Score:8/9
Altman Z-Score:2.75
Debt / Equity:0.00
Balance Sheet strength, Altman Z-Score & Piotroski F-Score checklist
Momentum
Moderate69/100
1Y Return:—
RSI (14):54.2
From 52W High:—
1-Year Relative Strength vs NIFTY 500, RSI-14 & 52W High distance
Quantitative Drivers & Growth Analysis
52-week corridor, deep valuation multiples, compounded CAGR trajectory, and institutional flow shifts
52-Week Low₹6,793.50
From 52W High-2.22%
52-Week High₹9,050.00
Valuation MultiplesCash Flow & Yield
PEG Ratio1.98
Earnings Yield1.18%
Price / FCF—
FCF Yield-27.81%
Payout Ratio19.20%
Net-Net Ratio-228.12
Solvency & SafetyPiotroski & Altman
Piotroski F-Score8/9
Altman Z-Score2.75
Graham Number₹1,243.59
1Y Flow & Margin ShiftsTrailing 12M
FII Stake:▼ 1.13%
DII Stake:▲ +0.68%
OPM Margin:▲ +0.98%
Net Margin:▲ +1.06%
Compounded Annual Growth Rate (CAGR Matrix)
Historical Fundamental Trajectory| Metric | QoQ Shift | YoY Shift | 1Y CAGR | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|---|
| Revenue Growth | ▲ +6.63% | ▲ +20.56% | 15.76% | 14.94% | 19.03% |
| Net Profit Growth | ▲ +9.69% | ▲ +34.17% | 34.29% | 33.34% | 66.80% |
| EPS Growth | ▲ +9.97% | ▲ +34.12% | 35.18% | 33.14% | 75.46% |
Intrinsic Valuation Models & DCF Sensitivity
Institutional DCF & Intrinsic Valuation Studio — APOLLOHOSP
2-Stage Discounted Cash Flow, Reverse DCF Implied Growth, and Benjamin Graham & Peter Lynch valuation benchmarks.
DCF Intrinsic Fair Value
₹402.2
Verdict:Overvalued (-95.5%)
Benjamin Graham Number
₹1,422.3
-83.9% vs CMPPeter Lynch Fair Value
₹1,441.5
-83.7% vs CMPReverse DCF Implied Growth
60.0% CAGR
Aggressive Expectations (Priced for Perfection)Valuation Spectrum PositioningCMP: ₹8,849.5
₹0 (Distress)CMP: ₹8,850DCF: ₹402Graham: ₹1,422
Scenario Calibration & Sensitivity Levers
Tune Discount Rate (WACC), 5-Year Growth, and Terminal Value to model bear, base, and bull cases.
Discount Rate (WACC)11.5%
Cost of Capital Hurdle
5-Year FCF Growth CAGR6.0%
Assumed stage-1 cash flow expansionTerminal Growth Rate4.5%
Long-term perpetual GDP growth rate5-Year Projected Cash Flow Schedule (₹ Cr)
| Projection Period | Growth Rate | Projected FCF | Discount Factor | Present Value |
|---|---|---|---|---|
| Year 1 | 6% | ₹951 | 0.8969 | ₹853 |
| Year 2 | 6% | ₹1,008 | 0.8044 | ₹811 |
| Year 3 | 6% | ₹1,068 | 0.7214 | ₹771 |
| Year 4 | 6% | ₹1,132 | 0.6470 | ₹733 |
| Year 5 | 6% | ₹1,200 | 0.5803 | ₹697 |
2D Sensitivity Matrix (WACC vs Terminal Growth Rate)
Click any cell to apply WACC & terminal growth scenario. Values in ₹ / share.| WACC \ g(Terminal) | 3.0% | 4.0% | 4.5% | 5.0% | 6.0% |
|---|---|---|---|---|---|
| 10.0% | ₹453 -95% | ₹588 -93% | ₹675 -92% | ₹778 -91% | ₹1063 -88% |
| 11.0% | ₹320 -96% | ₹419 -95% | ₹479 -95% | ₹550 -94% | ₹733 -92% |
| 11.5% | ₹266 -97% | ₹351 -96% | ₹402 -95% | ₹462 -95% | ₹613 -93% |
| 12.0% | ₹218 -98% | ₹291 -97% | ₹336 -96% | ₹386 -96% | ₹512 -94% |
| 13.0% | ₹136 -98% | ₹192 -98% | ₹226 -97% | ₹264 -97% | ₹355 -96% |
Discounted cash flow (DCF) and valuation models are quantitative projections based on user-supplied assumptions — not a forecast, not a guarantee of future performance, and not SEBI-registered investment advice. Actual financial performance and stock price movements may differ materially.
New to intrinsic valuation models? Learn how Discounted Cash Flow and Terminal Growth rates work.Read DCF Academy Guide →
Valuation history
P/E65.49current
ReportedComputed, approximate
P/B13.41current
ReportedComputed, approximate
The dashed line is computed from historical close price divided by the most recently reported annual EPS or book value — not IndianAPI's own figure, which only ever gives a single current reading with no history behind it. Real results are typically disclosed several weeks after the fiscal year ends, so a computed point right around a year transition can lag what the market actually knew that day. The solid line is the real reported figure.
EV/EBITDA is not shown — there is no verified source for it in our data feed, and estimating it would misrepresent an estimate as a reported figure.
| Date | P/E | P/B |
|---|---|---|
| 31 Aug 2026 | 65.49 | 13.41 |
Analyst Consensus, Price Targets & Forecasts
Analyst Consensus & Recommendations
Aggregated institutional equity research ratings · 31 Aug 2026
Strong Buy(1.74 / 5)
Strong Buy:12
Buy:11
Hold:3
Sell:1
Strong Sell:0
Coverage: 27 contributing analystsScale: 1 (Strong Buy) – 5 (Strong Sell)
Ratings shown are third-party analyst estimates compiled from institutional brokers. They do not constitute investment advice.
Risk Profile & Volatility
Statistical return volatility classification · 31 Aug 2026
Moderate risk
Low RiskModerate RiskHigh Risk
Annualised Standard Deviation:18.82%
Analyst Price Targets
12-month forward price consensus · 31 Aug 2026
Upside: +10.15%
Mean Target₹9,748.00vs CMP ₹8,849.50
High Target₹10,800.00+22.0% max upside
Low Target₹6,230.00-29.6% downside
Median Target₹10,000.0027 estimates
Low: ₹6,230.00Mean: ₹9,748.00High: ₹10,800.00
Mean Target Current Price (₹8,849.50)
Price targets are third-party analyst estimates compiled from institutional brokers. They do not constitute investment advice.
Forward Financial Forecasts & Consensus Estimates
Institutional broker consensus estimates and forward earnings trajectory
FY2024EConsensus
Mean Estimate
₹17.65
Low:—
High:—
FY2024EConsensus
Mean Estimate
₹11.59
Low:—
High:—
FY2024EConsensus
Mean Estimate
₹16.20
Low:—
High:—
FY2024EConsensus
Mean Estimate
₹17.06
Low:—
High:—
FY2025EConsensus
Mean Estimate
₹21.23
Low:—
High:—
FY2025E4 Analysts
Mean Estimate
₹26.34
Low:—
High:—
FY2025E6 Analysts
Mean Estimate
₹25.89
Low:—
High:—
FY2025E6 Analysts
Mean Estimate
₹27.10
Low:—
High:—
FY2026E7 Analysts
Mean Estimate
₹36.76
Low:—
High:—
FY2026E5 Analysts
Mean Estimate
₹33.19
Low:—
High:—
FY2026E6 Analysts
Mean Estimate
₹36.28
Low:—
High:—
FY2026E3 Analysts
Mean Estimate
₹30.10
Low:—
High:—
FY2027E4 Analysts
Mean Estimate
₹46.83
Low:₹44.00
High:₹49.00
FY2027E6 Analysts
Mean Estimate
₹40.37
Low:—
High:—
FY2027E4 Analysts
Mean Estimate
₹42.18
Low:₹35.00
High:₹45.00
FY2027E4 Analysts
Mean Estimate
₹47.81
Low:₹45.00
High:₹53.00
FY2028E1 Analysts
Mean Estimate
₹51.95
Low:₹51.00
High:₹51.00
| Period / Fiscal Year | Consensus Mean | Bull Case (High) | Bear Case (Low) | Brokers |
|---|---|---|---|---|
| FY2024 Forecast | ₹17.65 | — | — | — |
| FY2024 Forecast | ₹11.59 | — | — | — |
| FY2024 Forecast | ₹16.20 | — | — | — |
| FY2024 Forecast | ₹17.06 | — | — | — |
| FY2025 Forecast | ₹21.23 | — | — | — |
| FY2025 Forecast | ₹26.34 | — | — | 4 |
| FY2025 Forecast | ₹25.89 | — | — | 6 |
| FY2025 Forecast | ₹27.10 | — | — | 6 |
| FY2026 Forecast | ₹36.76 | — | — | 7 |
| FY2026 Forecast | ₹33.19 | — | — | 5 |
| FY2026 Forecast | ₹36.28 | — | — | 6 |
| FY2026 Forecast | ₹30.10 | — | — | 3 |
| FY2027 Forecast | ₹46.83 | ₹49.00 | ₹44.00 | 4 |
| FY2027 Forecast | ₹40.37 | — | — | 6 |
| FY2027 Forecast | ₹42.18 | ₹45.00 | ₹35.00 | 4 |
| FY2027 Forecast | ₹47.81 | ₹53.00 | ₹45.00 | 4 |
| FY2028 Forecast | ₹51.95 | ₹51.00 | ₹51.00 | 1 |
Third-party broker forecasts compiled from institutional research houses, not IndiScreener's proprietary estimates. Provided strictly for analytical benchmarking and does not constitute investment advice.
Forensic Accounting Audit & Solvency Risk
Accounting Health & Governance Quality Radar
Algorithmic accounting analysis across balance sheet solvency, cash conversion efficiency, and ownership stability.
Clean Governance & Solvency
Financial Strengths & Catalysts
4 Factors- •Company has delivered a high Return on Equity (ROE) of 20.5%.
- •Net profit has grown at an impressive 33.3% CAGR over 3 years.
- •Strong cash generation: Operating Cash Flow is 147.2% of reported Net Profit.
- •High institutional backing: FIIs & DIIs hold a combined 58.8%.
Risk Factors & Watchouts
1 Watchout- •Stock is trading at an elevated valuation multiple of 65.5x P/E.
Forensic Accounting & Health Audit
Piotroski F-Score, Altman Z-Score Distress Model & Beneish Earnings Manipulation Checks
Piotroski F-Score8 / 9
● Strong (High Quality)
Altman Z-Score2.75
● Safe Zone
Negligible risk of financial distress over the next 2 years.
Beneish M-Score-2.76
● Low Risk (Clean Accounting)
Cash flows closely match reported earnings with conservative accruals.
Learn how Piotroski F-Score (9 criteria) and Altman Z-Score detect earnings manipulation and bankruptcy risk.Read Forensic Guide →
10-Year Financial Statements & DuPont ROE
Financial Statements
consolidated · amounts in ₹ Crores
Accounting Flow:
Wall Street Cash Flow & Free Cash Flow (FCF) Cascade
FY26 (2025-2026)3-Stage institutional flow from reported earnings to owner Free Cash Flow and capital allocation
FCF Conversion Rate (FCF / PAT)
46.2%Low Cash Conversion
Measures how much reported accounting profit turns into real liquid cash.
Free Cash Flow Margin
3.6%of Gross Revenue
Liquid cash retained per ₹100 of top-line revenue generated.
CapEx Reinvestment Rate
68.6%of Operating Cash
Portion of operating cash reinvested in future capacity and maintenance.
Reported Net Profit (PAT)₹1,942 CrInflow
1,942
+ D&A Non-Cash Charge₹875 CrAdd-back
875
Working Capital Adjustment₹42 Cr+ Cash
42
= Operating Cash Flow (CFO)₹2,859 CrOperating Cash
2,859
- Capital Expenditures (CapEx)-₹1,962 CrReinvestment
1,962
= Free Cash Flow (FCF)₹897 CrFree Cash Flow
897
- Dividends & Debt Repayment-₹427 CrCapital Return
427
= Net Change in Cash₹470 CrNet Balance
470
Multi-Year Historical FCF vs Reported PAT Trajectory:
Free Cash Flow (FCF) Reported Net Profit (PAT)
| Metric | 2014-201531 Mar 2015 | 2015-201631 Mar 2016 | 2016-201731 Mar 2017 | 2017-201831 Mar 2018 | 2018-201931 Mar 2019 | 2019-202031 Mar 2020 | 2020-202131 Mar 2021 | 2021-202231 Mar 2022 | 2022-202331 Mar 2023 | 2023-202431 Mar 2024 | 2024-202531 Mar 2025 | 2025-202631 Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | ₹9,617.44 | ₹11,246.80 | ₹10,560.00 | ₹14,662.60 | ₹16,612.50 | ₹19,059.20 | ₹21,794.00 | ₹25,228.50 |
| Operating profit | — | — | — | — | ₹677.40 | ₹1,174.70 | ₹639.40 | ₹1,884.30 | ₹1,452.30 | ₹1,711.20 | ₹2,278.00 | ₹2,885.00 |
| OPM | — | — | — | — | 7.04% | 10.44% | 6.05% | 12.85% | 8.74% | 8.98% | 10.45% | 11.44% |
| Net profit | — | — | — | — | ₹236.05 | ₹454.80 | ₹150.40 | ₹1,055.60 | ₹819.10 | ₹898.60 | ₹1,445.90 | ₹1,941.70 |
| EPS | — | — | — | — | 17.02 | 23.48 | 8.20 | 59.34 | 57.78 | 62.58 | 100.88 | 136.37 |
| Net margin | — | — | — | — | 2.45% | 4.04% | 1.42% | 7.20% | 4.93% | 4.71% | 6.63% | 7.70% |
| ROE | — | — | — | — | 7.08% | 13.62% | 3.27% | 18.77% | 13.22% | 12.96% | 17.61% | 20.48% |
| ROCE | 12.00% | 9.00% | 8.00% | 7.00% | 9.37% | 13.05% | 6.82% | 17.39% | 13.08% | 14.16% | 14.17% | 18.36% |
| Debt / equity | — | — | — | — | 1.10 | 1.68 | 0.90 | 0.72 | 0.70 | 0.77 | 0.96 | 0.90 |
Compounded growth (CAGR)
| Metric | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|
| Revenue | 15.76% | 14.94% | 19.03% | — |
| Net profit | 34.29% | 33.34% | 66.80% | — |
| EPS | 35.18% | 33.14% | 75.46% | — |
Each column only appears when 12 real reported years actually support it — never extrapolated from fewer.
Balance sheet
| Metric | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | — | — | — | — | ₹9,183.07 | ₹11,338.40 | ₹11,416.70 | ₹13,269.30 | ₹14,427.80 | ₹16,753.10 | ₹20,657.40 | ₹22,196.90 |
| Total liabilities | — | — | — | — | ₹5,849.60 | ₹7,999.30 | ₹6,814.20 | ₹7,646.00 | ₹8,230.40 | ₹9,817.70 | ₹12,445.10 | ₹12,716.80 |
| Total equity | — | — | — | — | ₹3,333.47 | ₹3,339.10 | ₹4,602.50 | ₹5,623.30 | ₹6,197.40 | ₹6,935.40 | ₹8,212.30 | ₹9,480.10 |
| Total debt | — | — | — | — | ₹3,673.06 | ₹5,620.70 | ₹4,159.70 | ₹4,068.10 | ₹4,332.40 | ₹5,332.60 | ₹7,864.30 | ₹8,492.90 |
| Cash | — | — | — | — | — | ₹352.60 | ₹386.60 | ₹498.20 | ₹379.90 | ₹492.20 | ₹15.20 | ₹14.10 |
| Current assets | — | — | — | — | ₹2,281.73 | ₹2,646.90 | ₹3,641.30 | ₹4,060.60 | ₹4,337.00 | ₹5,279.70 | ₹7,028.90 | ₹6,899.80 |
| Current liabilities | — | — | — | — | ₹1,955.38 | ₹2,337.30 | ₹2,037.80 | ₹2,434.30 | ₹3,324.90 | ₹4,664.50 | ₹4,578.90 | ₹6,481.30 |
| Inventory | — | — | — | — | ₹641.97 | ₹817.90 | ₹327.60 | ₹523.00 | ₹516.70 | ₹622.50 | ₹671.50 | ₹640.00 |
| Receivables | — | — | — | — | ₹1,101.39 | ₹1,100.10 | ₹1,439.00 | ₹1,905.30 | ₹2,389.60 | ₹2,672.10 | ₹3,205.80 | ₹3,678.30 |
| Payables | — | — | — | — | ₹713.12 | ₹908.80 | ₹1,160.00 | ₹1,631.80 | ₹1,915.60 | ₹2,368.60 | ₹2,240.50 | ₹2,251.80 |
| Net PP&E | — | — | — | — | ₹5,415.56 | ₹7,260.90 | ₹6,545.70 | ₹7,288.60 | ₹8,033.80 | ₹9,385.20 | ₹10,586.70 | ₹12,030.10 |
| Retained earnings | — | — | — | — | ₹1,612.91 | ₹1,618.90 | ₹1,713.90 | ₹2,743.50 | ₹3,330.60 | ₹4,079.00 | ₹5,360.90 | ₹6,578.80 |
Cash flow
| Metric | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | — | — | — | — | ₹904.95 | ₹1,292.80 | ₹1,256.90 | ₹1,796.60 | ₹1,390.50 | ₹1,920.30 | ₹2,136.40 | ₹2,859.00 |
| Capital expenditure | — | — | — | — | — | ₹-513.00 | ₹-295.50 | ₹-657.20 | ₹-1,128.50 | ₹-1,136.80 | ₹-1,712.70 | ₹-1,962.00 |
| Free cash flow | — | — | — | — | — | ₹779.80 | ₹961.40 | ₹1,139.40 | ₹262.00 | ₹783.50 | ₹423.70 | ₹897.00 |
| OCF / net profit | — | — | — | — | 3.83 | 2.84 | 8.36 | 1.70 | 1.70 | 2.14 | 1.48 | 1.47 |
| FCF / Capex intensity | — | — | — | — | — | 4.56 | 2.80 | 4.48 | 6.79 | 5.96 | 7.86 | 7.78 |
Income statement detail
| Metric | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit | — | — | — | — | ₹4,956.57 | ₹5,747.90 | ₹4,875.80 | ₹7,089.10 | ₹8,038.20 | ₹9,253.70 | ₹10,484.00 | ₹12,152.90 |
| Cost of revenue | — | — | — | — | ₹4,660.86 | ₹5,498.90 | ₹5,684.20 | ₹7,573.50 | ₹8,574.30 | ₹9,805.50 | ₹11,310.00 | ₹13,075.60 |
| EBITDA | — | — | — | — | ₹1,072.31 | ₹1,793.80 | ₹1,211.90 | ₹2,484.40 | ₹2,067.10 | ₹2,397.60 | ₹3,034.90 | ₹3,760.40 |
| Income before tax | — | — | — | — | ₹373.54 | ₹660.00 | ₹220.70 | ₹1,578.10 | ₹1,143.70 | ₹1,362.50 | ₹2,006.10 | ₹2,616.00 |
| Interest expense | — | — | — | — | ₹267.16 | ₹447.40 | ₹379.20 | ₹268.30 | ₹240.50 | ₹272.20 | ₹252.10 | ₹194.10 |
| Tax expense | — | — | — | — | ₹173.37 | ₹225.20 | ₹84.70 | ₹477.00 | ₹256.20 | ₹445.50 | ₹534.00 | ₹658.20 |
| D&A | — | — | — | — | ₹394.91 | ₹619.10 | ₹572.50 | ₹600.10 | ₹614.80 | ₹686.40 | ₹756.90 | ₹875.40 |
| EBITDA margin | — | — | — | — | 11.15% | 15.95% | 11.48% | 16.94% | 12.44% | 12.58% | 13.93% | 14.91% |
Financial ratios
| Metric | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | — | — | — | — | 1.17 | 1.13 | 1.79 | 1.67 | 1.30 | 1.13 | 1.54 | 1.06 |
| Quick ratio | — | — | — | — | 0.84 | 0.78 | 1.63 | 1.45 | 1.15 | 1.00 | 1.39 | 0.97 |
| Interest coverage | — | — | — | — | 2.54 | 2.63 | 1.69 | 7.02 | 6.04 | 6.29 | 9.04 | 14.86 |
| Inventory days | 50.00 | 49.00 | 47.00 | 51.00 | 50.27 | 54.29 | 21.04 | 25.21 | 22.00 | 23.17 | 21.67 | 17.87 |
| Receivable days | 43.00 | 36.00 | 38.00 | 37.00 | 41.80 | 35.70 | 49.74 | 47.43 | 52.50 | 51.17 | 53.69 | 53.22 |
| Payable days | 59.00 | 66.00 | 51.00 | 55.00 | 55.85 | 60.32 | 74.49 | 78.64 | 81.55 | 88.17 | 72.31 | 62.86 |
| Cash conversion cycle | 34.00 | 19.00 | 34.00 | 33.00 | 36.23 | 29.67 | -3.71 | -6.01 | -7.05 | -13.82 | 3.05 | 8.22 |
| Working capital days | 24.00 | 16.00 | 27.00 | 8.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 |
| Fixed asset turnover | — | — | — | — | 1.78 | 1.55 | 1.61 | 2.01 | 2.07 | 2.03 | 2.06 | 2.10 |
| ROA | — | — | — | — | 2.57% | 4.01% | 1.32% | 7.96% | 5.68% | 5.36% | 7.00% | 8.75% |
| ROIC | — | — | — | — | — | 8.99% | 4.70% | 14.30% | 11.10% | 9.78% | 10.41% | 12.02% |
| Gross margin | — | — | — | — | 51.54% | 51.11% | 46.17% | 48.35% | 48.39% | 48.55% | 48.11% | 48.17% |
DuPont 3-Stage ROE Factor Decomposition
Deconstructing Return on Equity into Profitability, Asset Efficiency, and Financial Leverage
Balanced Return EngineFY2025-2026
Net marginProfitability
7.70%
Net Profit generated per ₹100 of revenue (Profitability)
×
Asset turnoverEfficiency
1.14
Revenue generated per ₹1 of total assets (Capital Efficiency)
×
Equity multiplierLeverage
2.34
Total assets supported per ₹1 of shareholder equity (Leverage)
=
Implied DuPont ROEFinal Output
20.48%
Reported: 20.48%
Explore the 3-Stage DuPont Formula: Net Margin × Asset Turnover × Leverage Multiplier.Read DuPont Guide →
Corporate Actions, Dividends & Capital Changes
Chronological Corporate Actions Registry
Historical stock splits, bonus shares, rights issues, and corporate schemes
| Year | Execution Date | Action Type | Ratio / Term |
|---|---|---|---|
| 2026 | 14 Aug 2026 | dividend | 200% |
| 16 Feb 2026 | dividend | 200% | |
| 2025 | 19 Aug 2025 | dividend | 200% |
| 15 Feb 2025 | dividend | 180% | |
| 2024 | 17 Aug 2024 | dividend | 200% |
| 20 Feb 2024 | dividend | 120% | |
| 2023 | 19 Aug 2023 | dividend | 180% |
| 24 Feb 2023 | dividend | 120% | |
| 2022 | 20 Aug 2022 | dividend | 235% |
| 2021 | 21 Aug 2021 | dividend | 60% |
| 2020 | 19 Sept 2020 | dividend | 55% |
| 26 Feb 2020 | dividend | 65% | |
| 2019 | 14 Sept 2019 | dividend | 120% |
| 14 Sept 2019 | dividend | 120% | |
| 2018 | 15 Sept 2018 | dividend | 100% |
| 15 Sept 2018 | dividend | 100% | |
| 2017 | 09 Sept 2017 | dividend | 120% |
| 2016 | 23 Mar 2016 | dividend | 120% |
| 2015 | 01 Aug 2015 | dividend | 115% |
| 2014 | 19 Aug 2014 | dividend | 115% |
| 2013 | 27 Jul 2013 | dividend | 110% |
| 2012 | 28 Jul 2012 | dividend | 80% |
| 2011 | 09 Jul 2011 | dividend | 75% |
| 2010 | 03 Sept 2010 | split | 5:10 |
| 17 Jul 2010 | dividend | 70% | |
| 2009 | 22 Aug 2009 | dividend | 65% |
| 2008 | 13 Aug 2008 | dividend | 60% |
| 2007 | 11 Aug 2007 | dividend | 20% |
| 24 Mar 2007 | dividend | 30% | |
| 2006 | 29 Jul 2006 | dividend | 45% |
Dividend Intelligence & Capital Return History
Historical cash payout track record across 10 dividend distributions
Latest Year DPS:₹20.00
Yield on CMP:0.23%
3Y Dividend CAGR:+10.1%
Annual Dividend Payout Progression (Per Share)Total Cumulative DPS: ₹84.75
₹20.0
2026
₹19.0
2025
₹16.0
2024
₹15.0
2023
₹11.8
2022
₹3.0
2021
| Ex-Date | Amount (Per Share) | Dividend Type |
|---|---|---|
| 14 Aug 2026 | ₹10.00 | Final |
| 16 Feb 2026 | ₹10.00 | Interim |
| 19 Aug 2025 | ₹10.00 | Final |
| 14 Feb 2025 | ₹9.00 | Interim |
| 16 Aug 2024 | ₹10.00 | Final |
| 20 Feb 2024 | ₹6.00 | Interim |
| 18 Aug 2023 | ₹9.00 | Final |
| 24 Feb 2023 | ₹6.00 | Final |
| 18 Aug 2022 | ₹11.75 | Final |
| 18 Aug 2021 | ₹3.00 | Final |
Industry Peer Group & Valuation Spread
Compare valuation multiples and market cap relative to sector competitors
HealthcareCompare Peers in Studio
Market Cap1,27,335.69 ₹ cr
Beats 97% of 65 industry peers · median 21,553.63 ₹ cr
P/E65.49 x
Beats 68% of 60 industry peers · median 48.58 x
P/B13.41 x
Beats 81% of 62 industry peers · median 6.13 x
ROE7.72%
Beats 26% of 65 industry peers · median 14.40%
ROCE9.72%
Beats 28% of 65 industry peers · median 16.66%
Debt to Equity0.36 x
Beats 62% of 65 industry peers · median 0.31 x
Net Margin14.41%
Beats 69% of 65 industry peers · median 13.15%
Dividend Yield0.23%
Beats 28% of 53 industry peers · median 0.44%
Revenue Growth (YoY)20.56%
Beats 56% of 64 industry peers · median 19.05%
| Company | Market Cap ▼ | P/E | P/B |
|---|---|---|---|
Sun Pharmaceutical Industries Ltd.SUNPHARMA | ₹4.61 L | 41.52 | 5.51 |
Torrent Pharmaceuticals Ltd.TORNTPHARM | ₹1.88 L | 79.00 | 20.38 |
Zydus Lifesciences Ltd.ZYDUSLIFE | ₹1.16 L | 23.78 | 4.42 |
Cipla Ltd.CIPLA | ₹1.14 L | 29.66 | 3.34 |
Laurus Labs Ltd.LAURUSLABS | ₹1.05 L | 117.32 | 19.65 |
Peers are chosen strictly by industry classification. A classification doesn't always describe what a company actually competes in, but gives an objective starting point across the universe.
Regulatory Filings & Market Intelligence
Corporate Filings & Document Vault
SEBI LODR VerifiedAudited Annual Reports, Investor Decks, Earnings Concall Transcripts, and Board Resolutions for Apollo Hospitals Enterprise Ltd. (APOLLOHOSP)
Indexed Documents6 Filings
Latest Disclosure02 Aug 2026
Shareholding02 Aug 2026
Apollo Hospitals Enterprise Ltd: Quarterly Statement of Shareholding Pattern filed with NSE/BSE
Secretarial Filing21 Jun 2026
Apollo Hospitals Enterprise Ltd: Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015
Board Outcome15 Jun 2026
Apollo Hospitals Enterprise Ltd: Outcome of Board Meeting for Approval of Audited Financial Results
AGM / EGM12 May 2026
Apollo Hospitals Enterprise Ltd: Notice of Annual General Meeting and Record Date for Dividend
Concall Transcript28 Mar 2026
Apollo Hospitals Enterprise Ltd: Transcript of Earnings Conference Call with Institutional Investors
News
- IndianAPIStock market today: Gift Nifty hints a weak start; eight day trading stocks to buy on Monday, 17 August
Indian stock indices Sensex and Nifty 50 are set to open lower on August 17 due to weak global signals. The Gift Nifty indicated a subdued start, trading below previous closes. Geopolitical tensions and oil prices remain critical factors affecting market sentiment.
- IndianAPIApollo Hospitals beats estimates for Q1FY27, net profit up 34%
Apollo Hospitals' Q1FY27 net profit rose 34% to ₹581 crore, beating street estimates, as high-complexity specialty volumes and pharmacy growth lifted revenue 21% to ₹7,043 crore.
- IndianAPISensex falls 388 points, Nifty 50 ends below 24,500; rising oil prices, Middle East confusion weigh
The Sensex fell 388 points, or 0.49%, to end at 78,154, while the Nifty 50 settled 112 points, or 0.46%, lower at 24,472. Nifty Midcap 100 index slipped 0.02%, while the Smallcap 100 index rose 0.22%.
- IndianAPISensex falls 388 points, Nifty 50 ends below 24,500; rising oil prices, Middle East confusion weigh
The Sensex fell 388 points, or 0.49%, to end at 78,154, while the Nifty 50 settled 112 points, or 0.46%, lower at 24,472. Nifty Midcap 100 index slipped 0.02%, while the Smallcap 100 index rose 0.22%.
- IndianAPIStocks to buy for short term: Mahindra and Mahindra among 3 shares Amol Athawale of Kotak Securities recommends
Amol Athawale from Kotak Securities identifies three stocks with growth potential, including Mahindra and Mahindra. With key support levels and upward momentum indicated by technical analysis, now appears to be the time to pay attention to these market movers.
- IndianAPIStocks to buy for short term: Mahindra and Mahindra among 3 shares Amol Athawale of Kotak Securities recommends
Amol Athawale from Kotak Securities identifies three stocks with growth potential, including Mahindra and Mahindra. With key support levels and upward momentum indicated by technical analysis, now appears to be the time to pay attention to these market movers.
- IndianAPIStock market today: Sensex jumps 500 points, Nifty 50 closes above 24,400; investors earn ₹2 lakh crore in a day
The Sensex ended 521 points, or 0.67%, higher at 78,285, while the Nifty 50 closed at 24,430, up 160 points, or 0.66%. The mid and small-cap segments also rose. The Nifty Midcap 100 and Smallcap 100 indices gained 0.45% and 0.75%, respectively.
- IndianAPIStock market today: Sensex jumps 500 points, Nifty 50 closes above 24,400; investors earn ₹2 lakh crore in a day
The Sensex ended 521 points, or 0.67%, higher at 78,285, while the Nifty 50 closed at 24,430, up 160 points, or 0.66%. The mid and small-cap segments also rose. The Nifty Midcap 100 and Smallcap 100 indices gained 0.45% and 0.75%, respectively.
- IndianAPIStock market today: Sensex gains 260 points, Nifty 50 ends above 24,250; IT, pharma shine
Stock market today: The Sensex ended 262 points, or 0.34%, higher at 77,763.91, while the Nifty 50 rose by 95 points, or 0.39%, to end at 24,270.85.
- IndianAPIStock market today: Sensex gains 260 points, Nifty 50 ends above 24,250; IT, pharma shine
Stock market today: The Sensex ended 262 points, or 0.34%, higher at 77,763.91, while the Nifty 50 rose by 95 points, or 0.39%, to end at 24,270.85.
- IndianAPIDoctor-led Magnet Hospitals debuts, signs up 8 hospitals
Magnet Hospitals, has debuted with an initial portfolio of eight city hospitals. The platform is backed by an initial investment of ₹224 crore, funded by Madhavan as the primary investor.
- IndianAPIDoctor-led Magnet Hospitals debuts, signs up 8 hospitals
Magnet Hospitals, has debuted with an initial portfolio of eight city hospitals. The platform is backed by an initial investment of ₹224 crore, funded by Madhavan as the primary investor.
- IndianAPIStock market today: Sensex falls 400 points, Nifty 50 ends below 23,950; Reliance, Kotak Mahindra Bank among top drags
The Sensex ended the day 372 points, or 0.48%, lower at 76,728.37, while the Nifty 50 settled at 23,946.25, down 110 points, or 0.46%. The Nifty Midcap 100 index dropped 0.37%, while the Smallcap 100 index declined 0.62%.
- IndianAPIStock market today: Sensex falls 400 points, Nifty 50 ends below 23,950; Reliance, Kotak Mahindra Bank among top drags
The Sensex ended the day 372 points, or 0.48%, lower at 76,728.37, while the Nifty 50 settled at 23,946.25, down 110 points, or 0.46%. The Nifty Midcap 100 index dropped 0.37%, while the Smallcap 100 index declined 0.62%.
- IndianAPISensex drops 700 points from day's high to close flat, Nifty 50 ends near 24,050; mid, small-caps underperform
Stock market today: The Sensex dropped 703 points from its intraday high of 77,803.18 to end at 77,100.47. The Nifty 50 hit an intraday high of 24,261.60 during the session but closed at 24,056, up 34 points, or 0.14%.
- IndianAPISensex drops 700 points from day's high to close flat, Nifty 50 ends near 24,050; mid, small-caps underperform
Stock market today: The Sensex dropped 703 points from its intraday high of 77,803.18 to end at 77,100.47. The Nifty 50 hit an intraday high of 24,261.60 during the session but closed at 24,056, up 34 points, or 0.14%.
- IndianAPISensex falls 479 points, Nifty 50 ends at 23,914; mid, small-caps outperform
Stock market today: The Sensex lost 479 points, or 0.63%, to close at 76,009.70, while the NSE counterpart Nifty 50 shed 118 points, or 0.49%, to settle at 23,913.70.
- IndianAPISensex falls 479 points, Nifty 50 ends at 23,914; mid, small-caps outperform
Stock market today: The Sensex lost 479 points, or 0.63%, to close at 76,009.70, while the NSE counterpart Nifty 50 shed 118 points, or 0.49%, to settle at 23,913.70.
- IndianAPIShares to buy or sell: Chandan Taparia of Motilal Oswal recommends three stocks to buy today - 22 May 2026
Shares to buy or sell: Chandan Taparia has recommended three stocks to buy today, 22 May 2026 - Apollo Hospitals Enterprise, KEI Industries and Samvardhana Motherson International shares.
- IndianAPIShares to buy or sell: Chandan Taparia of Motilal Oswal recommends three stocks to buy today - 22 May 2026
Shares to buy or sell: Chandan Taparia has recommended three stocks to buy today, 22 May 2026 - Apollo Hospitals Enterprise, KEI Industries and Samvardhana Motherson International shares.
For informational and educational purposes only. Not investment advice. Data may be delayed or incomplete. Consult a SEBI-registered investment adviser before making investment decisions.